Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.39 |
| ▸ | PTPRC | P08575 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CETP | P11597 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2923558 | 0.88 | HDAC1 (0.39) | LTA4HEPHX2HDAC1ALDH1A1MEN1 | |
| SCHEMBL4689225 | 0.83 | LMNA (0.46) | PTPN1PTPRCSYKALDH1A1KMT2A | |
| SCHEMBL9042229 | 0.83 | LMNA (0.46) | PTPN1PTPRCSYKALDH1A1KMT2A | |
| SCHEMBL3379309 | 0.81 | SMN1; SMN2 (0.41) | PTPN1PTPRCSYKALDH1A1MEN1 | |
| SCHEMBL192403 | 0.80 | MAOB (0.50) | LTA4HALDH1A1MEN1KMT2A | |
| SCHEMBL3063043 | 0.77 | MEN1 (0.36) | HDAC1ALDH1A1MEN1KMT2A | |
| SCHEMBL4688233 | 0.75 | PTPN1 (0.41) | LTA4HPTPN1PTPRCSYKALDH1A1 | |
| SCHEMBL3378133 | 0.74 | CA12 (0.41) | PTPN1SYKHDAC1HDAC3HDAC2 | |
| SCHEMBL7561030 | 0.73 | GLA (0.42) | LTA4HSYKALDH1A1 | |
| SCHEMBL4683881 | 0.73 | SYK (0.47) | LTA4HEPHX2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427635-B2 | Substituted hydantoins | HOFFMANN-LA ROCHE INC. (US) | 2008-09-23 | — | — | US | disclosed |
| EP-1781649-B1 | SUBSTITUTED HYDANTOINS | HOFFMANN LA ROCHE (CH) | 2008-08-13 | — | — | EP | disclosed |
| EP-1781649-A2 | SUBSTITUTED HYDANTOINS | F. Hoffmann-Roche AG (CH) | 2007-05-09 | — | — | EP | disclosed |
| US-20060041146-A1 | Substituted hydantoins | HOFFMANN-LA ROCHE AG | 2006-02-23 | — | — | US | disclosed |
| WO-2006018188-A2 | SUBSTITUTED HYDANTOINS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041146-A1 | Substituted hydantoins | HNMT, MAPK6, KYNU | LTA4H 928/4885EPHX2 99/4885PTPN1 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.